Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chaowanachan, Thanyanan ^a   Krogstad, Emily ^a   Ball, Cameron ^a   Woodrow, Kim A ^a  

^a University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NANOPARTICLE; POLYGLACTIN; SAQUINAVIR; TENOFOVIR;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; EXPLANT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; INFECTION PREVENTION; MUCOSA; NANOEMULSION; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; REPRODUCIBILITY; VIRUS INHIBITION; ZETA POTENTIAL;

ADENINE; ANIMALS; ANTI-HIV AGENTS; BENZOXAZINES; CELL LINE; CERVIX UTERI; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LACTIC ACID; MACACA; MODELS, BIOLOGICAL; NANOPARTICLES; ORGANOPHOSPHONATES; PARTICLE SIZE; POLYGLYCOLIC ACID; SAQUINAVIR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE CULTURE TECHNIQUES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876427946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061416     Document Type: Article

References (64)

1. McMichael AJ, Haynes BF, (2012) Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology 13: 423-427.
2. Hladik F, McElrath MJ, (2008) Setting the stage: host invasion by HIV. Nature Reviews Immunology 8: 447-457.
3. Joint United Nations Programme on HIV/AIDS and World Health Organization (2009) AIDS epidemic update. Geneva: UNAIDS. 21-22.
4. Quinn TC, Overbaugh J, (2005) HIV/AIDS in women: An expanding epidemic. Science 308: 1582-1583.
5. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, et al. (2008) Perspective- HIV vaccine research: The way forward. Science 321: 530-532.
6. Karim SSA, Kashuba ADM, Werner L, Karim QA, (2011) Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378: 279-281.
7. Kim PS, Read SW, (2010) Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 2: 693-702.
8. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR, (2010) Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines. Antiviral Research 88: S55-S66.
9. Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, et al. (2000) Antiretroviral therapy in adults- Updated recommendations of the International AIDS Society-USA Panel. Jama-Journal of the American Medical Association 283: 381-390.
10. Dou (2007) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery (vol 108, pg 2827, 2006). Blood 109: 1816-1816.
11. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, et al. (2006) Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835.
12. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, et al. (2010) Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. Journal of Neuroimmune Pharmacology 5: 592-601.
13. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, et al. (2009) NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine 4: 903-917.
14. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC, (2011) Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection. Antimicrobial Agents and Chemotherapy 55: 1831-1842.
15. Mallipeddi R, Rohan LC, (2010) Progress in antiretroviral drug delivery using nanotechnology. International Journal of Nanomedicine 5: 533-547.
16. das Neves J, Amiji MM, Bahia MF, Sarmento B, (2010) Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Advanced Drug Delivery Reviews 62: 458-477.
17. Wong HL, Chattopadhyay N, Wu XY, Bendayan R, (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Advanced Drug Delivery Reviews 62: 503-517.
18. Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, et al. (2011) Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. Journal of Controlled Release 150: 204-211.
19. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, et al. (2001) P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Molecular Pharmacology 59: 806-813.
20. Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, et al. (2007) Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Aids Research and Human Retroviruses 23: 988-995.
21. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A, (2009) Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation. Antimicrobial Agents and Chemotherapy 53: 896-902.
22. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, et al. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601.
23. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20: 543-551.
24. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, et al. (2008) Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. Plos Medicine 5: 1238-1250.
25. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, et al. (2001) Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. Aids Research and Human Retroviruses 17: 1167-1173.
26. Parikh UM, Dobard C, Sharma S, Cong ME, Jia HW, et al. (2009) Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine. Journal of Virology 83: 10358-10365.
27. Bilati U, Allemann E, Doelker E, (2005) Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. European Journal of Pharmaceutical Sciences 24: 67-75.
28. Bilati U, Allemann E, Doelker E, (2003) Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharmaceutical Development and Technology 8: 1-9.
29. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E, (2004) Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharmaceutical Research 21: 1428-1439.
30. Mudigonda K, Jukanti R, Apte SS, Ajjala DR, Shrivastava W, et al. (2006) HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. Biomedical Chromatography 20: 1028-1032.
31. Owen DH, Katz DF, (1999) A vaginal fluid simulant. Contraception 59: 91-95.
32. Takeuchi Y, McClure MO, Pizzato M, (2008) Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research. Journal of Virology 82: 12585-12588.
33. Derdeyn CA, Decker JM, Sfakianos JN, Wu XY, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. Journal of Virology 74: 8358-8367.
34. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, (1998) Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. Journal of Virology 72: 2855-2864.
35. Wei XP, Decker JM, Liu HM, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy 46: 1896-1905.
36. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, et al. (1995) Growth of macrophage-tropic and primary human immodeficiency virus type 1 (HIV-1) isolates in a unique CD4(+) T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. Journal of Virology 69: 3712-3720.
37. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC, (2009) Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles. Pharmaceutical Research 26: 502-511.
38. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ, (2009) Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrobial Agents and Chemotherapy 53: 1797-1807.
39. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 58: 621-681.
40. Cummins JE, Guarner J, Flowers L, Guenthner PC, Bartlett J, et al. (2007) Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrobial Agents and Chemotherapy 51: 1770-1779.
41. Rohan LC, Moncla BJ, Ayudhya R, Cost M, Huang Y, et al. (2010) In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide. PLoS One 5.
42. Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins JE, et al. (2005) A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. Journal of Infectious Diseases 192: 1545-1556.
43. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, et al. (2011) Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy 66: 354-357.
44. Leo A, Hansch C, Elkins D, (1971) Partition coefficients and their uses. Chemical Reviews 71: 525-+.
45. Lindenberg M, Kopp S, Dressman JB, (2004) Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics 58: 265-278.
46. American Society for Testing and Materials (1985) Zeta Potential of Colloids in Water and Waste Water. ASTM Standard D pp. 4187-4182.
47. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, et al. (2009) Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nature Materials 8: 526-533.
48. Jain RA, (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475-2490.
49. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, et al. (2009) Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. Bmc Infectious Diseases 9.
50. Mert O, Lai SK, Ensign L, Yang M, Wang YY, et al. (2012) A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. Journal of Controlled Release 157: 455-460.
51. Lai SK, Suk JS, Pace A, Wang YY, Yang M, et al. (2011) Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials 32: 6285-6290.
52. Feng JY, Ly JK, Myrick F, Goodman D, White KL, et al. (2009) The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6.
53. Panyam J, Labhasetwar V, (2003) Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharmaceutical Research 20: 212-220.
54. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V, (2002) Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb Journal 16.
55. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA, (2010) Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice. Journal of Antimicrobial Chemotherapy 65: 2183-2187.
56. Greco WR, Bravo G, Parsons JC, (1995) The search for synergy: a critical review from a response surface perspective. Pharmacological Reviews 47: 331-385.
57. Remmel RP, Kawle SP, Weller D, Fletcher CV, (2000) Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clinical Chemistry 46: 73-81.
58. Noble S, Faulds D, (1996) Saquinavir- A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52: 93-112.
59. Flexner C, (2000) Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology 40: 649-674.
60. Kuo YC, Yu HW, (2011) Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. Colloids and Surfaces B-Biointerfaces 88: 627-634.
61. Shah LK, Amiji MM, (2006) Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharmaceutical Research 23: 2638-2645.
62. Chen XQ, Venkatesh S, (2004) Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharmaceutical Research 21: 1758-1761.
63. das Neves J, Michiels J, Arien KK, Vanham G, Amiji M, et al. (2012) Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. Pharmaceutical Research 29: 1468-1484.
64. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, et al. (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature Medicine 18: 446-U211.